medigraphic.com

2014, Number 4

<< Back Next >>

Enf Infec Microbiol 2014; 34 (4)

Leptospirosis, a revision of clinical manifestations in patients attended in high specialty hospital, Dr. Gustavo A. Rovirosa Pérez, Tabasco state, during the period 2007 to 2011

Valencia SN, Camargo JA, Muñoz PH

Language: Spanish
References: 12
Page: 126-131
PDF size: 159.07 Kb.


ABSTRACT

Introduction. Leptospirosis is an infectious disease caused by a spirochete genus Leptospira sp. comprising 24 serogroup and 250 serovars. It has been reported a fatality rate of up to 22%.
Materials and methods. From September 2007 to December 2011, 43 clinical records of discharged patients with presumptive diagnosis of leptospirosis were reviewed. Suspected case was considered with a MAT positive test greater than or equal to 1:80.
Results. 21 cases (48.83%) were positive by any of the serovars of Leptospira identified. Of the 21 positive patients, 14 cases (66.6%) had a benign or anicteric form, 7 cases (33.3%) were severe and of these, 4 patients (19.04%) had Weil’s disease.
Conclusions. It is important to consider in those patients with acute febrile illness accompanied by hepatic and renal involvement, with thrombocytopenia with or without bleeding manifestations the possible presence of Leptospira sp.


REFERENCES

  1. 1.-Raghavan U.M. Palaniappan, Ramanujam S and Chang YF. “Leptospirosis: pathogenesis, immunity, and diagnosis”. Current Opinion in Infectious Diseases 2007; 20: 284–292.

  2. 2.-House HR, Ehlers JP. “Travel Infections”. Emerg Med Clin N Am 2008; 26: 499-516.

  3. 3.-NOM-029-SSA2-1999 para la vigilancia epidemiológica, prevención y control de la Leptospirosis en el Humano. Estados Unidos Mexicanos. Secretaria de Salud. México.

  4. 4.-Trivedi SV, Vasava AH, Bhatia LC, Patel TC, et al. “Plasma Exchange with immunosupression in pulmonary alveolar haemorrhage due to leptospirosis”. Indian J Med Res 2010; 429-433.

  5. 5.-Trivedi SV, Vasava AH, Patel TC, Bhatia LC. “Cyclophosphamide in pulmonary alveolar hemorrhage due to leptospirosis”. Indian J Crit Care Med 2009; 13 (2): 79-84.

  6. 6.-Marquez M, Valera B. et al. “Afectación pulmonar en la leptospirosis”. Archivos de Bronconeumología 2006; 42: 202-204.

  7. 7.-Myers MD. Manual de Métodos para el Diagnostico de laboratorio de la Leptospirosis. Centro Panamericano de Zoonosis. OPS. 1985; 30.

  8. 8.-Zúñiga C, Iván R, y cols. “Casos de Leptospirosis posterior a la gran inundación en el Municipio de Centro, Estado de Tabasco, 2007”. Enf Inf Microbiol.2011;31(1): 33-37.

  9. 9.-Herve Dupont, Deborah D-P, Jean LP, Sophie Z-H, Bruno J et al. “Leptospirosis: Prognostic Factors Associated with Mortality”. Clinical Infectious Diseases 1997; 25:720-724.

  10. 10.-Chi Wei Yang. “Leptospirosis in Taiwan. An Undersestimated Infectious Disease”. Chang Gung Med Journal. 2007; 30 (2): 109-114.

  11. 11.-Griffith M. Hospenthal D. et.al. “Antimicrobial therapy of leptospirosis. Hemorrhage due to leptospirosis”. Current Opin Infect Dis. 2006; 19: 533-537.

  12. 12.-Paul N. Levet, David A. Haake. “Leptospira Species (leptospirosis)” en: Principles and Practice of Infectious Diseases. Philadelphia, PA. Ed. Churchil Linvingstone. Elsevier.2010:305




2020     |     www.medigraphic.com